Major Novartis Shareholder Calls for Board Shake-Up After Drug Trial Setbacks

3-line summary

• A major Novartis shareholder called for a board shake-up after recent drug trial setbacks, according to an exclusive Investing.com report.
• This follows Novartis's earlier-reported failed cholesterol drug trial and subsequent biopharma stock selloff.

This summary is our own processing of the source article; see the source link below for full context.